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ABSTRACT
Cancer cells have developed unique strategies to meet their high energy demand. 
Therefore, they have established a setting of Ca2+-triggered high mitochondrial activity. 
But mitochondrial Ca2+ uptake has to be strictly controlled to avoid mitochondrial 
Ca2+ overload that would cause apoptotic cell death. Methylation by protein arginine 
methyl transferase 1 (PRMT1) desensitizes the mitochondrial Ca2+ uptake machinery 
and reduces mitochondrial Ca2+ accumulation in cancer cells. In case of PRMT1-
driven methylation, proper mitochondrial Ca2+ uptake is reestablished by increased 
activity of uncoupling protein 2 (UCP2), pointing to an importance of these proteins 
for cancer cell survival and activity. Accordingly, in this study we investigated the 
impact of UCP2 and PRMT1 on the fate of human lung cancer cells (A549, Calu-3 and 
H1299) as well as on patients suffering from lung carcinoma. We show that combined 
overexpression of UCP2 and PRMT1 significantly enhances viability, proliferation as 
well as mitochondrial respiration. In line with these findings, the overall survival 
probability of lung carcinoma patients with high mRNA expression levels of UCP2 
and PRMT1 is strongly reduced. Furthermore, analysis via The Cancer Genome Atlas 
(TCGA) reveals upregulation of both proteins, UCP2 and PRMT1, as common feature 
of various cancer types. These findings suggest that proper mitochondrial Ca2+ uptake 
is essential for devastating tumor growth, and highlight the importance of a tightly 
controlled mitochondrial Ca2+ uptake to ensure proper ATP biosynthesis while avoiding 
dangerous mitochondrial Ca2+ overload. By that, the study unveils proteins of the 
mitochondrial Ca2+ uptake as potential targets for cancer treatment.
INTRODUCTION
Although more than 100 distinct types of cancer 
are known, cancer cells share similar molecular 
characteristics, including loss of cell cycle control, 
resulting in nearly unlimited replication potential, tissue 
invasion and metastases [1]. Uncontrolled proliferation of 
cancer cells comes along with an increased energy demand 
[2]. For a long time, glycolysis was assumed to be the 
main source of energy in cancer cells [3]. However, a less 
active form of pyruvate kinase isoenzyme M2 (PKM2) 
seems to be the bottleneck in glycolysis of cancer cells 
[4]. By the reduced conversion of phosphoenolpyruvate 
to pyruvate, less active PKM2 limits the production of 
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adenosine triphosphate (ATP) from glycolysis, but boosts 
the accumulation of intermediate products like nucleic 
acids, phospholipids and serines as essential “building 
blocks” for cancer cells [4]. Cancer cells with less active 
PKM2 have to rely on ATP production via oxidative 
phosphorylation (OXPHOS) in mitochondria. This non-
glycolytic metabolic pathway for energy supply is fueled 
by amino acids as well as by fatty acids that are entering 
the citrate cycle and firing mitochondrial respiration [4]. 
Notably, mitochondria’s highly efficient ATP production is 
outranging anaerobic glycolysis and is especially attractive 
for cells with elevated energy demands [5]. The activity of 
the mitochondrial respiration chain is strongly reliant on 
Ca2+-dependent dehydrogenases of the citrate cycle in the 
mitochondrial matrix [6]. In line with that, constitutive 
Ca2+ flux from the ER to mitochondria was demonstrated 
to be essential to maintain viability of cancer cells with 
high proliferation activity [7]. The importance of the ER-
mitochondrial Ca2+ transfer in cancer cells was further 
highlighted by the finding that several tumor suppressors, 
including p53, manipulate contact sites between these 
two organelles in regions of mitochondria-associated-ER 
membranes (MAMs), where ER and mitochondria are in 
close proximity to each other to ensure Ca2+ and lipid flux 
[8, 9]. Recently, we showed that common cancer cell lines 
exhibit a stronger tethering between mitochondria and 
ER in comparison to non-cancerous cells, which makes 
them more vulnerable for mitochondrial Ca2+ overload, 
induced by, for instance, the polyphenol resveratrol [10]. 
However, cancer cells seem to have a unique strategy 
to protect themselves against lethal mitochondrial Ca2+ 
accumulation. Methylation of the mitochondrial Ca2+ 
uptake 1 (MICU1) [11], a protein controlling the activity 
of the mitochondrial Ca2+ uniporter (MCU) [12], by 
protein arginine methyl transferase 1 (PRMT1) causes a 
strong sensitivity loss of the mitochondrial Ca2+ uptake 
machinery in cancer cells and counteracts the risk of 
mitochondrial Ca2+ overload [13]. Nevertheless, to ensure 
sufficient mitochondrial Ca2+ uptake, the uncoupling 
protein 2 (UCP2) is able to normalize mitochondrial Ca2+ 
uptake in case of PRMT1-driven methylation of MICU1 
in cancer cells [13]. Accordingly, we hypothesize that 
cancer cells develop an exclusive strategy for balancing 
mitochondrial Ca2+ uptake through the expression pattern 
of UCP2 and PRMT1 in order to meet the Ca2+ demand 
of the dehydrogenases to fuel OXPHOS, while protecting 
themselves from lethal mitochondrial Ca2+ accumulation. 
In line with our hypothesis, recent studies have already 
linked the expression of either UCP2 or PRMT1 to tumor 
growth, state of metastasis and chemo resistance [14-
16]. In this study, we considered the recent reports on 
the functional interaction of UCP2 and PRMT1 [13] and 
investigated the importance of this relation on cancer cell’s 
viability, proliferation and patient’s survival. 
RESULTS
Combined overexpression of UCP2 and PRMT1 
increases cell viability and proliferation of human 
lung cancer cells
Since mitochondrial Ca2+ uptake is essential for 
mitochondrial metabolic activity, we manipulated the 
expression of PRMT1 and UCP2, proteins known to affect 
the mitochondrial Ca2+ uptake machinery, to investigate 
their effect on human non-small-cell lung cancer cell lines 
A549, Calu-3 and H1299. Origin of each cell lines was 
validated by Sanger sequencing [Supplementary Figure 
1A]. Knockdown or overexpression, verified by qRT-PCR 
[Supplementary Figure 1B], of either UCP2 or PRMT1 
alone did not affect cell viability and apoptotic caspase 
3/7 activity. Combined depletion of UCP2 and PRMT1 
by specific siRNAs strongly decreased cell viability 
[Figure 1A], whereas activity of apoptotic caspases 3/7 
was significantly increased [Figure 1B]. In contrast, 
overexpression of both proteins improved cell viability 
and diminished apoptotic caspase 3/7 activity. In line 
with these data, cancer cell proliferation was significantly 
enhanced by combined overexpression of UCP2 and 
PRMT1 in comparison to cells with double knockdown 
[Figure 1C]. 
Combined overexpression of UCP2 and PRMT1 
results in enhanced mitochondrial respiration 
activity
Based on our previous work [13], we assume 
that this positive impact of UCP2 and PRMT1 on 
cancer cell viability and proliferation is due to a more 
efficient mitochondrial respiration. Therefore, OCR was 
determined after addition of metabolic modulators. Indeed, 
A549 [Figure 2A], Calu-3 [Figure 2B] as well as H1299 
[Figure 2C] cells with combined overexpression of UCP2 
and PRMT1 had an enhanced maximal mitochondrial 
respiration, representing an increased capacity to create 
ATP via mitochondrial respiration, in comparison to cells 
with transient knockdown of UCP2 and PRMT1, whereas 
the basal rate of glycolysis (ECAR) was not altered 
[Figure 2D].
Survival rate of lung carcinoma patients is 
influenced by expression of UCP2 and PRMT1
Since viability as well as proliferation of lung cancer 
cells were strongly affected by expression levels of UCP2 
and PRMT1, we analyzed the survival of lung carcinoma 
patients with different mRNA expression patterns of UCP2 
and PRMT1. The median value of mRNA expression was 
Oncotarget80280www.impactjournals.com/oncotarget
Figure 1: Impact of UCP2 and PRMT1 on cell viability, caspase activity and proliferation of lung carcinoma cell 
lines. Cell viability of A549 (left panel), Calu-3 (middle panel) and H1299 (right panel) cells with knockdown of UCP2 or PRMT1 and/
or overexpression of UCP2 and PRMT1 was measured via Celltiter-Blue assay and calculated as percentage of viable cells normalized to 
control condition a. Caspase activity of A549 (left panel), Calu-3 (middle panel) and H1299 (right panel) cells, treated with siRNA against 
UCP2 or PRMT1 and/or overexpressing UCP2 and PRMT1, was measured by Caspase 3/7-Glo assay and normalized to control conditions 
b. Cellular proliferation of A549 (left panel), Calu-3 (middle panel) and H1299 (right panel) cells diminished of UCP2 and PRMT1 and/or 
overexpressing these proteins was determined by counting cells 48 h after seeding and cell number was normalized to control condition c. 
Bar graphs represent mean +/- SEM (n=3).
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used as cutoff value and the patient group was divided 
into four cohorts (PRMT1-high/UCP2-high; PRMT1-
low/UCP2-low; PRMT1-high/UCP2-low; PRMT1-low/
UCP2-high), whose overall survival time was analyzed. 
The overall survival probability [Figure 3A] was strongly 
decreased in the cohort with mRNA expression levels 
of both, PRMT1 and UCP2, above the median value in 
comparison to the group with low expression levels of 
both genes (p = 0.023). High mRNA expression of one 
of these genes already negatively affected overall survival 
(PRMT1-high/UCP2-low vs. PRMT1-low/UCP2-
low: p=0.0406; PRMT1-low/UCP2-high vs. PRMT1-
low/UCP2-low: p=0.16), but not in such an extent as 
combined high mRNA expression of PRMT1 and UCP2. 
In particular, 43% of patients with simultaneously high 
PRMT1 and UCP2 expression, while 70% of patients with 
simultaneously low PRMT1 and UCP2 expression were 
alive at 5 years follow-up.
Combined upregulation of UCP2 and PRMT1 as 
a common feature of numerous cancer types
Our results from cell viability experiments with 
human lung carcinoma cells as well as analysis of lung 
carcinoma patient’s overall survival reveal a positive 
impact of UCP2 and PRMT1 on cancer cells. Therefore, 
we investigated whether high mRNA expression levels 
of UCP2 and PRMT1 are a common feature in cancerous 
tissues. Analysis of The Cancer Genome Atlas (TCGA) 
database revealed an increase in UCP2 as well as in 
PRMT1 mRNA expression in several tumor tissues in 
comparison to adjacent normal tissue [Figure 3B]. Only 
prostate adenocarcinoma was found to have low levels 
of PRMT1 mRNA expression. Notably, in this particular 
type of cancer also UCP2 expression was lower than in 
the adjacent normal tissue, possibly demonstrating that the 
mRNA expression of UCP2 and PRMT1 is dependent on 
the respective other protein [Figure 3B].
DISCUSSION
Recently, we have shown that PRMT1-driven 
methylation of MICU1 desensitizes the mitochondrial Ca2+ 
uptake machinery and, therefore, reduces mitochondrial 
Ca2+ accumulation in cancer cells [13]. Hence, under 
these conditions proper mitochondrial Ca2+ uptake is 
reestablished by UCP2 that normalizes the sensitivity of 
MICU1 and, thus, reestablishes normal mitochondrial 
Figure 2: Mitochondrial respiration and basal rate of glycolysis in different lung carcinoma cell lines. Oxygen consumption 
rate (OCR) of A549 (n=6) a., Calu-3 (n=5) b. and H1299 (n=6) c. cells with either combined overexpression or knockdown of UCP2 
and PRMT1. 2 µM Oligomycin, 0.3 µM FCCP and 2.5 µM Antimycin A were injected as indicated. Bar graphs (mean +/- SEM) represent 
maximal mitochondrial respiration (max. mito. respiration) of the different cells. Rate of basal extracellular acidification (ECAR) of A549 
(left panel, n=6), Calu-3 (middle panel, n=5) and H1299 (right panel, n=6) cells was presented as bar graphs (mean +/- SEM ) d.
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Ca2+ uptake [13]. Since an increased tethering between 
mitochondria and the biggest internal Ca2+ store, the 
ER, was found in cancer cells [10], we hypothesize 
that cancer cells with high levels of PRMT1-driven 
methylation control their mitochondrial Ca2+ uptake via 
UCP2 to ensure suitable mitochondrial ATP production 
by stimulating dehydrogenases with a proper amount of 
Ca2+. Elevated levels of mitochondrial respiration in lung 
carcinoma cells with combined overexpression of UCP2 
and PRMT1 are in line with this suggestion. The finding 
that viability and proliferation of lung carcinoma cells 
was strongly increased in case of upregulated PRMT1 
and UCP2 expression further supports a link between 
the expression of these two proteins and cancer cells’ 
perilousness. In line with this assumption, cancer cells 
depleted from PRMT1 and UCP2 showed an increased 
vulnerability and exhibited a largely decreased cell 
viability and proliferation. The remarkably high levels 
of apoptotic caspase activity in these cells are likely a 
result of PRMT1-uncontrolled mitochondrial Ca2+ uptake 
and cell death by mitochondrial Ca2+ overload due to the 
enhanced tethering between the ER and mitochondria in 
these cells [10]. Notably, unaltered cell viability, apoptotic 
caspase activity and proliferation in cells depleted of 
Figure 3: Survival analysis of lung carcinoma patients and mRNA expression analysis. Overall survival probability of 
lung carcinoma patients was analyzed in regard to the individual mRNA expression of UCP2 and PRMT1 (UCP2-high/PRMT1-high 
vs. UCP2-high/PRMT1-low vs. UCP2-low/PRMT1-high vs. UCP2-low/PRMT1-low) and presented as Kaplan-Meier survival plot a. 
mRNA expression levels of UCP2 and PRMT1 in different cancer types were determined via TCGA analysis and presented as bar graphs, 
normalized to mRNA expression levels of UCP2 and PRMT1 in adjacent normal tissue (BreastCa/breast invasive carcinoma: n=114; 
ThyroidCa/thyroid carcinoma: n=59; LungCa/lung carcinoma: n=109; BladderCa/bladder urothelial carcinoma: n=19; LiverCa/liver 
hepatocellular carcinoma: n=50; HeadCa/head and neck squamous cell carcinoma: n=43; ColonCa/colorectal adenocarcinoma: n=32; 
ProstateCa/prostate cancer: n=52) b.
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either UCP2 or PRMT1, might point to a still functional 
interrelation between both proteins as recently described 
[13]. These results obtained from cell culture experiments 
are in line with our overall survival analyses of patients 
suffering from lung cancer, which has already been linked 
to a strongly altered Ca2+ homeostasis [17]. In particular, 
the negative correlation of survival probability of patients 
with the expression of UCP2 and PRMT1 supports our 
hypothesis about the impact of proper mitochondrial Ca2+ 
uptake on the metabolic efficiency of cancer cells that 
affects cancer abrasiveness and patient survival. On the 
other hand, the present data suggest that cancer cells in the 
patient cohort with low levels of UCP2 and PRMT1 might 
be metabolically less active, yielding attenuated cancer 
cell proliferation and, thus, increased patient survival. The 
overall survival of patients with high mRNA expression 
levels of PRMT1 alone was already significantly 
reduced in comparison to those patients with low mRNA 
expression levels of PRMT1 and UCP2. Therefore, we 
conclude that protection from mitochondrial Ca2+ overload 
by a PRMT1-controlled mitochondrial Ca2+ uptake is 
already a major advantage for cancer cells. Improper 
mitochondrial Ca2+ accumulation as Achilles’ heel of 
cancer cells has been already reported: i, in prostate cancer 
cells, mitochondrial Ca2+ overload was proven to strongly 
enhance apoptosis, induced by TRAIL (TNFα related 
apoptosis inducing ligand) [18]. Notably, prostate cancer 
was the only cancer type found in our TCGA analysis with 
low levels of PRMT1, which makes this specific cancer 
probably more vulnerable for mitochondrial Ca2+ overload. 
ii, the expression levels of MICU1 was shown to correlate 
with the overall survival of ovarian cancer patients as 
well as cancer cell chemoresistance against cisplatin [19]. 
iii, in triple-negative breast cancer, the most aggressive 
type of breast cancer, upregulation of the channel forming 
protein responsible for mitochondrial Ca2+ uptake, MCU, 
was demonstrated to positively correlate with tumor size 
and lymph node infiltration [20]. One might argue, that 
overexpression of MCU might lead to mitochondrial 
Ca2+ overload and apoptosis as in prostate cancer cells, 
but, breast cancer is well known for a strong upregulation 
of PRMT1 [21], also confirmed by our TCGA analysis, 
which might protect cancer cells from Ca2+ overload via 
MICU1 methylation. iv, strongly elevated UCP2 levels 
have been linked to poorly differentiated breast cancer, 
indicating that similar as MCU also UCP2 helps breast 
cancer cells to proliferate, migrate and invade [14]. 
Therefore, a combined upregulation of PRMT1 and UCP2 
as crucial risk in various cancer types, as found in our 
TCGA analysis, seems to be reasonable. 
All together, these findings suggest that proper 
mitochondrial Ca2+ uptake might be essential for 
devastating tumor growth, and highlight the importance of 
a tightly-controlled mitochondrial Ca2+ uptake to prevent 
mitochondrial Ca2+ overload and, ultimately, cell death. 
Our study reveals a major role of PRMT1 and UCP2 in 
cancer cell viability and proliferation as well as in patients’ 
overall survival probability, indicating that numerous 
different cancer types utilize upgraded mitochondrial Ca2+ 
uptake to meet their greatly enhanced energy demand. 
Accordingly, targeting mitochondrial Ca2+ uptake proteins 
by newly developed compounds against distinct members 
of the mitochondrial Ca2+ uptake machinery would allow a 
personalized therapy that considers individual expression 
pattern in the very tumor, in order to efficiently evoke 
cancer cell injury and increased susceptibility against 
therapeutics. 
MATERIALS AND METHODS
Cell culture, sanger sequencing and transfection
H1299 cells were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) from Sigma Aldrich (Vienna, 
Austria), A549 and Calu-3 cells in a 1:1 mixture of 
Ham‘s F12 and DMEM. Media were supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, 100 µg/
ml streptomycin and 1.25 µg/ml amphotericin B (Gibco, 
Lifetechnologies; Vienna, Austria). To verify the origin of 
the various cell lines, cell lysates were sent to Microsynth 
(Balgach, Switzerland) for Sanger sequencing. Cells were 
transiently transfected at a confluence of 60 - 80% with 
1.5 µg plasmid DNA encoding UCP2 or PRMT1 as well 
as with 100 µM siRNA UCP2 or PRMT1 using 2.5 µl 
of TransFastTM transfection reagent (Promega; Madison, 
WI, US) in 1 ml of serum- and antibiotic-free medium. 
Transfection mix was replaced by full culture medium 
after 24 hours. All experiments were performed 48 hours 
after transfection. siRNAs were obtained from Microsynth, 
and their sequences (5′-3′) were as follows: UCP2 
5’-CACTGTCGACGCCTACAAGACCATC-3’, 
‘5’-GTCATAGGTCACCA 
GCTCAGCACAG-3’; PRMT1: 
5’-TGCTCAACACCGTGCTCTATGC-3’, 
5’-TCCTCGA 
TGGCCGTCACATACA-3’.
mRNA isolation and qRT-PCR
Total RNA from cells was isolated using the 
PEQLAB total RNA isolation kit (Erlangen, Germany) 
and reverse transcription was performed using a cDNA 
synthesis kit (Applied Biosystems; Foster City, CA). 
qRT-PCR was performed using QuantiFast SYBR Green 
RT-PCR kit (Qiagen; Hilden, Germany) as described 
previously [13]. Primers for qRT-PCR were obtained from 
Invitrogen (Vienna, Austria), and their sequences (5′-3′) 
were: UCP2 forward, TCCTGAAAGCCAACCTCATG; 
UCP2 reverse, GGCAGAGTTCATGTATCTCGTC; 
PRMT1 forward, TGCTCAACACCGTGCTTATGC; 
PRMT1 reverse, TCCTCGATGGCCGTCACATACA
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Cell viability and apoptosis assay
For cell viability and apoptosis assays, cells were 
plated 24 h after transfection on 96-well plates at a density 
of 5,000 cells/well. Cell viability was measured 48 h after 
transfection using CellTiter-Blue assay and apoptotic 
caspase activity was determined by using the Caspase-
Glo® 3/7 assay (Promega; Madison, WI, US) as reported 
previously [10]. 
Proliferation assays
For proliferation determination, cells were plated 
24 h after transfection on 6-well plates at a density of 
8,000 cells/well. Number of cells was counted 48 h after 
transfection and presented as percentage of control cell 
proliferation.
Measurement of mitochondrial respiration
24 h after transfection, A546, Calu-3 and H1299 
cells were plated on Cell-Tak™ coated XF96 polystyrene 
cell culture microplates (Seahorse Bioscience®, Agilent; 
California, US) at a density of 50,000 cells per well. After 
24 h cells were washed and pre-incubated in XF assay 
medium supplemented with 1 mM sodium pyruvate, 
2 mM glutamine and 5.5 mM D-glucose. Oxygen 
consumption rate (OCR) and extracellular acidification 
rate (ECAR) were subsequently measured every 7 min 
using an XF96 extracellular flux analyzer. After 15 min 
basal measurement, Oligomycin [2 µM], FCCP [0.3 
µM] and Antimycin A [2.5 µM] were injected. Oxygen 
consumption was normalized to protein content (pmol O2/
(min×μg protein)). 
Clinical data acquisition
According to mRNA expression of PRMT1 and 
UCP2, Kaplan-Meier survival plots presenting the survival 
of lung carcinoma patients were calculated using data from 
Gene Expression Omnibus (GEO). Patient samples were 
split into four groups regarding expression of the indicated 
genes (median as cutoff value). These four patient cohorts 
were compared by a Kaplan-Meier survival plot and 
logrank P values were calculated. 
Data acquisition via Xena
The mRNA expression levels of the genes coding for 
PRMT1 and UCP2 in various tumor tissues were obtained 
as RNA SeqV2 RSEM values through UCSC Xena 
(https://xenabrowser.net/) as The Cancer Genome Atlas 
(Provisional, TCGA) datasets in April 2017. The selected 
genomic profile was ‘gene expression RNAseq (polyA+ 
IlluminaHiSeq)’ and the entered gene set was a user-
defined list. Expression levels of normal and tumor tissue 
samples with the same sample ID were matched [22]. The 
mRNA expression levels of tumor tissues were normalized 
to the mRNA expression levels of corresponding adjacent 
healthy tissue samples from the same patient (100% 
value). Patients with missing expression levels of normal 
or tumor tissues were excluded.
Statistical analysis
The statistical analysis was performed with 
GraphPad Prism 5.0 using the unpaired Student’s t-test, 
and p<0.05 was considered to be significant.
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